ARCHANA TRIVEDI: Open Payments
NPI 1104068261 · SACRAMENTO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,587 in 111 payments from 16 companies in 2025. Trend: 2023 $1,982 · 2024 $2,018 · 2025 $2,587
Food & beverage: $2,587
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 16 | $354 |
| Teva Pharmaceuticals USA, Inc. | 9 | $321 |
| Otsuka America Pharmaceutical, Inc. | 11 | $293 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $256 |
| Axsome Therapeutics, Inc. | 11 | $236 |
| ABBVIE INC. | 16 | $197 |
| Bausch Health US, LLC | 9 | $195 |
| Supernus Pharmaceuticals, Inc. | 13 | $186 |
| Lundbeck LLC | 8 | $180 |
| E.R. Squibb & Sons, L.L.C. | 1 | $123 |
Products named: REXULTI, INGREZZA, CAPLYTA, Auvelity, VRAYLAR, APLENZIN, AUSTEDO XR, Qelbree.
Industry payments across CA — which companies pay providers there.
